49 results on '"Volpi A"'
Search Results
2. WS17.06 Two years of elezacaftor/tezacaftor/ivacaftor treatment show only a partial anti-inflammatory effect in patients with cystic fibrosis
3. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial
4. WS06.04 Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
5. EPS5.09 Changes in nutritional status and muscular strength in adult patients with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ETI)
6. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis
7. Bronchiectases at early chest computed tomography in children with cystic fibrosis are associated with increased risk of subsequent pulmonary exacerbations and chronic pseudomonas infection
8. 92 Developing a sustainable team model in uncertain times
9. 623 Preliminary assessment of nasal and colon-derived primary cells theratyping for a personalized medicine approach in people with cystic fibrosis carrying ultra-rare genotypes
10. 509 Cystic fibrosis transmembrane conductance regulator positively regulates angiotensin-converting enzyme 2 expression and SARS-CoV-2 viral entry into airway epithelial cells: Implications for patients with cystic fibrosis
11. Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers
12. P027 Effects of ivacaftor therapy confirm the results of theratyping using rectal and nasal epithelial cells of a cystic fibrosis patient carrying the ultra-rare CFTR genotype W57G (c.169T > G)/A234D (c.701C > A)
13. P159 Modifications of anthropometric parameters and body composition after Kaftrio® in a group of adolescents and young adults
14. P159 Modifications of anthropometric parameters and body composition after Kaftrio® in a group of adolescents and young adults
15. Whole blood fatty acid analysis with micromethod in cystic fibrosis and pulmonary disease
16. 623 Preliminary assessment of nasal and colon-derived primary cells theratyping for a personalized medicine approach in people with cystic fibrosis carrying ultra-rare genotypes
17. 509 Cystic fibrosis transmembrane conductance regulator positively regulates angiotensin-converting enzyme 2 expression and SARS-CoV-2 viral entry into airway epithelial cells: Implications for patients with cystic fibrosis
18. 92 Developing a sustainable team model in uncertain times
19. WS06.4 Early Pseudomonas aeruginosa (Pa) isolation impacts on N2-Multiple Breath Washout (MBW) and body mass index (BMI) percentile in children with cystic fibrosis
20. P183 Increase of HLA-G in plasma of cystic fibrosis paediatric patients treated with Docosahexaenoic acid (DHA)
21. WS04.2 Electronic nose (E-nose) analysis of systemic volatile organic compounds (VOCs) pattern distinguishes paediatric patients with cystic fibrosis (CF) from healthy controls (HC) and depicts disease status
22. WS06.4 Early Pseudomonas aeruginosa (Pa) isolation impacts on N2-Multiple Breath Washout (MBW) and body mass index (BMI) percentile in children with cystic fibrosis
23. WS04.2 Electronic nose (E-nose) analysis of systemic volatile organic compounds (VOCs) pattern distinguishes paediatric patients with cystic fibrosis (CF) from healthy controls (HC) and depicts disease status
24. P183 Increase of HLA-G in plasma of cystic fibrosis paediatric patients treated with Docosahexaenoic acid (DHA)
25. WS12-6 Evaluating appropriate PROMs in CARE-CF-1 trial: Lynovex® (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacebations
26. ePS4.01 Open randomised study on docosahexaenoic acid, 5-methyltetrahydrofolate and vitamin B12 supplementation in cystic fibrosis paediatric patients: focus on fatty acids, inflammation and blood cell membranes
27. WS12-6 Evaluating appropriate PROMs in CARE-CF-1 trial: Lynovex® (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacebations
28. ePS3.01 Long-term effects of non-invasive ventilation for airway clearance in cystic fibrosis
29. ePS3.01 Long-term effects of non-invasive ventilation for airway clearance in cystic fibrosis
30. ePS4.01 Open randomised study on docosahexaenoic acid, 5-methyltetrahydrofolate and vitamin B12 supplementation in cystic fibrosis paediatric patients: focus on fatty acids, inflammation and blood cell membranes
31. P054 Human reservoirs of pathogens colonising the airways of cystic fibrosis patients
32. P128 Lung transplantation in paediatric patients with cystic fibrosis: a single centre experience
33. WS19.6 N2-MBW in CF patients with chronic lung bacterial colonizations
34. P054 Human reservoirs of pathogens colonising the airways of cystic fibrosis patients
35. WS19.6 N2-MBW in CF patients with chronic lung bacterial colonizations
36. WS03.3 A phase II, randomised, double-blind, placebo-controlled, crossover study of dry powder mannitol in children with cystic fibrosis (CF)
37. WS13.4 Chest HRCT (cCT) score predicts later Pseudomonas infection in young children with cystic fibrosis
38. WS03.3 A phase II, randomised, double-blind, placebo-controlled, crossover study of dry powder mannitol in children with cystic fibrosis (CF)
39. Efficacy of peripheral deposition of inhaled rhDNase in CF patients during a respiratory tract exacerbation
40. 275 Eating habits and nutritional intervention in CF adolescents
41. WS13.4 Chest HRCT (cCT) score predicts later Pseudomonas infection in young children with cystic fibrosis
42. Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers
43. 275 Eating habits and nutritional intervention in CF adolescents
44. 75* Small airways response to domase alfa improves using controlled inhalation: a randomized controlled trial in cystic fibrosis patients
45. Efficacy of peripheral deposition of inhaled rhDNase in CF patients during a respiratory tract exacerbation
46. Dietary intake and DXA total body measurements in children and adolescents with cystic fibrosis
47. 75* Small airways response to domase alfa improves using controlled inhalation: a randomized controlled trial in cystic fibrosis patients
48. Listing patients to lung transplantation (LTx). Experience of 110 cases in the CF Center of Verona
49. Dietary intake and DXA total body measurements in children and adolescents with cystic fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.